SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [31] SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Moon, Jun Sung
    Hong, Jun Hwa
    Jung, Yong Jin
    Ferrannini, Ele
    Nauck, Michael A.
    Lim, Soo
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2022, 33 (06) : 424 - 442
  • [32] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Cardoso, Pedro
    Young, Katie G.
    Nair, Anand T. N.
    Hopkins, Rhian
    Mcgovern, Andrew P.
    Haider, Eram
    Karunaratne, Piyumanga
    Donnelly, Louise
    Mateen, Bilal A.
    Sattar, Naveed
    Holman, Rury R.
    Bowden, Jack
    Hattersley, Andrew T.
    Pearson, Ewan R.
    Jones, Angus G.
    Shields, Beverley M.
    McKinley, Trevelyan J.
    Dennis, John M.
    DIABETOLOGIA, 2024, 67 (05) : 822 - 836
  • [33] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [34] Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
    Brown, Emily
    Wilding, John P. H.
    Barber, Thomas M.
    Alam, Uazman
    Cuthbertson, Daniel J.
    OBESITY REVIEWS, 2019, 20 (06) : 816 - 828
  • [35] Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
    Cignarelli, Angelo
    Genchi, Valentina Annamaria
    Le Grazie, Giulia
    Caruso, Irene
    Marrano, Nicola
    Biondi, Giuseppina
    D'Oria, Rossella
    Sorice, Gian Pio
    Natalicchio, Annalisa
    Perrini, Sebastio
    Laviola, Luigi
    Giorgino, Francesco
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [36] SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
    Gurgle, Holly E.
    White, Karen
    McAdam-Marx, Carrie
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 239 - 249
  • [37] Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions
    Zhu, Jing-Jing
    Wilding, John P. H.
    Gu, Xiao-Song
    WORLD JOURNAL OF DIABETES, 2024, 15 (10)
  • [38] The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes
    Gillard, Pieter
    Schnell, Oliver
    Groop, Per-Henrik
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 170
  • [39] Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer, Milton
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (05) : 461 - 463
  • [40] Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
    Arnold, Suzanne V.
    Tang, Fengming
    Cooper, Andrew
    Chen, Hungta
    Gomes, Marilia B.
    Rathmann, Wolfgang
    Shimomura, Iichiro
    Vora, Jiten
    Watada, Hirotaka
    Khunti, Kamlesh
    Kosiborod, Mikhail
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
12345